Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 9—September 2011

Research

Seroepidemiologic Study of Pandemic (H1N1) 2009 during Outbreak in Boarding School, England

Sandra Johnson, Chikwe IhekweazuComments to Author , Pia Hardelid, Nika Raphaely, Katja Hoschler, Alison Bermingham, Muhammad Abid, Richard Pebody, Graham Bickler, John Watson, and Éamonn O’Moore
Author affiliations: Author affiliations: Health Protection Agency, London, UK (S. Johnson, C. Ihekweazu, P. Hardelid, K. Hoschler, A. Bermingham, R. Pebody, G. Bickler, J. Watson); Health Protection Agency, Oxfordshire, UK (N. Raphaely, M. Abid, É. O’Moore)

Main Article

Table 3

Multivariable analysis of all study participants in relation to having ARI or serology-confirmed infection during outbreak of pandemic (H1N1) 2009, England*

Variable AOR (95% CI) for ARI in questionnaire sample AOR (95% CI) for positive test result in matched sample
Age group, y
13–15 1 1
16–18 1.57 (0.98–2.53) 1.85 (0.95–3.60)
20–49 1.00 (0.53–1.89) 0.30 (0.12–0.73)
>50
0.66 (0.32–1.34)
0.20 (0.08–0.53)
Took antiviral drugs for PEP†
No 1
Yes
0.41 (0.27–0.61)
0.55 (0.30–0.99)
Seasonal Influenza vaccine
No 1 1
Yes 1.01 (0.63–1.62) 1.81 (0.91–3.59)

*For ARI, n = 654 who completed questionnaires; for serology-confirmed infection, n = 333 who completed questionnaires and had a matched serology sample. ARI, acute respiratory infection; AOR, adjusted odds ratio; CI, confidence interval; PEP, postexposure prophylaxis.
†Persons who reported taking treatment dose of antiviral agents were excluded.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO